Micronoma’s microbiome platform is breaking into its next phase with validation from the U.S. Food and Drug Administration. Last month, the San Diego-based company announced that the FDA has given its OncobiotaLUNG assay Breakthrough Device Designation. The...
The FDA has granted breakthrough device designation to the novel, microbiome-driven, liquid biopsy assay OncobiotaLUNG for the detection of lung carcinomas, according to a press release from developer Micronoma.1 The assay is one of the first blood microbiome–driven...
The FDA has granted the OncobiotaLUNG assay a breakthrough device designation for the early detection of lung cancer. The FDA has provided the OncobiotaLUNG assay a breakthrough device designation, according to the device maker, Micronoma.1 The OncobiotaLUNG assay is...
Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA). As a...
We’ll start with the acquisition: This week, daily e-newsletter Morning Brew announced that it had acquired One Future, a digital media startup, with the hopes of tapping a larger Gen Z audience. The companies declined to disclose terms of the deal. Our Future...
